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Hepatocellular carcinoma (HCC) accounts for 
approximately 90% of primary liver cancers and, with 
rapidly increasing incidence in the last two decades, 
constitutes a major global health problem [1,2]. Its 
pathogenesis is based on multifactorial mechanisms of 
chronic liver injury and inflammation, such as HBV/HCV 
infection, alcohol abuse, non-alcoholic steatohepatitis 
(NASH), aflatoxin intoxication, or congenital metabolic 
disorders [1,2]. As a result, up to 90% of HCC develops in 
the context of liver cirrhosis, which further complicates 
the therapeutic management of these patients due to the 
inherent risk of post-treatment liver failure [1,2]. In recent 
years, the prognosis of HCC patients has progressively 
improved thanks to multimodal interventions in 
prevention, diagnosis, and therapy [1,2]. HBV vaccination 
campaigns and the implementation in clinical practice of 
direct acting agents (DAA) against HCV have effectively 
controlled the most impactful oncogenic triggers for HCC. 
Statistical models have also been developed to predict 
the probability of HCC occurrence in patients with chronic 
liver diseases [3]. In 2014, Johnson et al. proposed a 
serum biomarker-based statistical model for estimating 
the likelihood of HCC in these patients. The GALAD model 
considers serum biomarkers such as AFP, AFP-L3, and des-
γ-carboxyprothrombin (DCP) in combination with gender 
and age [4,5]. Its accuracy becomes even more specific 
when an AFP glycoform specific for malignant tumors and 
HCC inflammation and a prothrombin precursor, which 
makes it possible to distinguish HCC from non-malignant 
liver diseases, are also analysed.
Imaging technology advances have enhanced the 
diagnostic power of multiphasic computed tomography 
(CT) scan, dynamic contrast-enhanced magnetic resonance 
imaging (MRI), and contrast-enhanced ultrasound 
(CEUS) scan [1,2,6]. The American College of Radiology 
has developed the Liver Imaging Reporting and Data 
System (LI-RADS), which is a comprehensive system for 
standardizing the acquisition, interpretation, reporting, 
and data collection of liver imaging [7]. According to LI-
RADS, diagnostic hallmarks of HCC include arterial phase 
hyperenhancement, non-peripheral venous or delayed 
phase washout appearance, enhancing capsule appearance, 
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and threshold growth. Importantly, imaging criteria apply 
only to patients with cirrhosis or current/prior HCC, and 
for nodules >1 cm. In these cases, the prevalence of HCC 
is sufficiently high and the diagnostic performance of 
imaging sufficiently precise that lesions meeting imaging 
criteria for HCC have close to 100% probability of being 
HCC [7]. Once the diagnosis is established, prognostic 
assessment is a critical step in the clinical decision making 
of HCC management, evaluating not only tumor stage but 
also liver function and performance status. 
The current European Association for the Study of the 
Liver Clinical Practice Guidelines endorse the Barcelona 
Clínic Liver Cancer (BCLC) staging system [1]. Hepatic 
resection may be a potentially curative therapy for patients 
with good performance status, preserved liver function, and 
solitary tumor of any size with no evidence of gross vascular 
invasion. In these cases, liver resection is associated with 
a 5-year survival rate of about 70% [1]. However, tumor 
recurrence can be observed in 50–70% of cases within 5 
years following surgery, either as intrahepatic metastases 
(often within 2 years following surgery) or as new HCC in 
the remaining cirrhotic liver (occurring more often beyond 
2 years) [1]. When the severity of the underlying liver 
disease or the presence of multiple HCCs contraindicate 
hepatic resection, liver transplantation (LT) may be 
considered under specific selection criteria [1,2]. The 
Milan criteria (one lesion < 5 cm; alternatively, up to three 
lesions, each <3 cm; no extrahepatic manifestations; no 
evidence of macrovascular invasion) currently represent 
the benchmark for the selection of patients with HCC 
for orthotopic LT [1,2]. The potential curative effect of 
LT for both the tumor and the underlying liver disease 
is responsible for the best therapeutic outcome for 
these patients, with a patient survival rate over 70% and 
tumor recurrence of 10-15% at 5-year follow up [1,2]. In 
those cases with a tumor limited to the liver and with no 
macrovascular invasion but unresectable and beyond the 
selection criteria for LT, trans-arterial chemoembolization 
(TACE) is considered the first-line treatment, either as a 
down staging strategy for LT indication or as a definitive 
therapy, with a reported median survival of 40 months 
[1,2].
The therapeutic management of HCC patients so far has 
been mainly based on surgery (hepatic resection and LT) 
or interventional radiology (ablation, TACE), rather than 
on systemic therapies which have usually been reserved for 
advanced-stage tumors [1,2]. Thus, the diagnostic work-up 
has been primarily targeted to assess tumor morphologic 
features such as nodules number, max diameter, presence 
of satellite nodules or macrovascular invasion, rather than 
precise biologic behaviour. As a matter of fact, liver biopsy 
is not routinely performed, and its indication is restricted 
to cases of nodules highly suspicious for malignancy but 
not completely meeting imaging criteria for HCC, or of non-
cirrhotic patients with suspected HCC lesions [1,2]. The 
main reason for limiting liver biopsies in HCC is the risk of 
adverse events possibly impacting on the diagnostic and/
or therapeutic pathway [8-10]. These variably comprise 
bleeding, bile leakage, and the potential risk of neoplastic 
seeding, although incidence is low [8-10]. In particular, 
the risk of tumor seeding along the needle path has been 
reported in less than 1% of cases, and its clinical impact 
in most cases was successfully controlled by resective or 
ablative treatments [8-10]. 
However, recent advances in our understanding of the 
biomolecular mechanisms implicated in the pathogenesis 
of HCC are now identifying potential therapeutic targets 
which may provide new and revolutionary therapeutic 
opportunities. 
Sorafenib and Lenvantinib, multikinase inhibitors 
blocking 40 kinases including vascular endothelial growth 
factor receptor 2 (VEGFR2) and BRAF, are considered as 
targeted first-line therapies for patients with advanced 
HCC and those with intermediate-stage (BCLC B) disease 
not eligible for, or progressing despite locoregional 
therapies [1,2]. Other multikinase inhibitors that block 
the activity of protein kinases involved in angiogenesis, 
oncogenesis, and tumor microenvironment, such as 
Regorafenib and Cabozantinib, are considered as targeted 
second-line therapies for patients with advanced HCC who 
have tolerated Sorafenib but progressed. All these drugs 
have been shown to improve survival and decrease the 
relative risk of death compared with placebo in patients 
with advanced HCC not amenable by the standard-of-care 
curative therapies (resection, transplantation, or ablation) 
(Table 1) [1,2].
The recent success of checkpoint inhibitors in 
different tumors has stimulated several ongoing clinical 
trials of different checkpoint inhibitors in HCC [1,2]. 
Immunotherapy with Nivolumab—that targets PD-1—can 
be considered in patients who are intolerant to, or have 
progressed under approved tyrosine kinase inhibitors, 
demonstrating a response rate of 17% and time to 
progression of 6.5 months with median survival close to 16 
months in second-line patients; this compares favourably 
with all the previously reported phase III second-line 
trials in HCC [1,2]. Meanwhile, a phase II trial of another 
anti-PD-1 antibody—pembrolizumab—as a second-line 
treatment (KEYNOTE-224) has recently been reported. 
The 16.3% response rate (RECIST v1.1) and 78% 6-month 
overall survival (OS) observed among the 104 patients 
studied are in line with the results seen with Nivolumab 
(Table 1) [1,2].
Adoptive T cell therapy (ATC) is an immunotherapeutic 
strategy targeted to specifically activate the host cellular 
immunity against tumor-associated antigens. It has 
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emerged as a highly effective treatment in the management 
of both hematological and virus-associated cancers [17]. On 
the other hand, solid tumors tend to show a high grade of 
resistance to ACT, mainly due to a genomic heterogeneity 
and instability resulting in loss of target-specific antigens 
expression, as well as due to a hypoxic, proinflammatory 
and immunosuppressive tumor microenvironment 
(TME) [17]. However, recent studies have highlighted 
that targeted therapies may not only inhibit molecular 
or biochemical pathways crucial for tumor growth and 
maintenance, but also disrupt the TME and enhance the 
local immune reactivity. Therefore, the combination of 
target therapies and ACT may represent the key point 
to significantly enhance the therapeutic outcome in the 
management of solid tumors [17].
A significant limitation in the HCC treatment is the 
absence of early diagnostic markers. Small tumoral masses 
with a diameter of less than 3 cm have over a 50% chance 
to be cured via surgical resection or thermal ablation. 
Nevertheless, the identification of these tumoral areas is 
still problematic due to the absence of pathognomonic 
symptoms in early stages of HCC. To overcome the 
problem, over the years, several laboratories have 
investigated molecules with a potential diagnostic impact 
as well as a possible therapeutic output when targeted. 
Among the most interesting categories of biomarkers 
studied have been oncogenes and tumor-suppressor genes 
[18]; plasma methylated DNA [19]; microRNA (miRNA) 
and long non-coding RNA (lncRNA) [20]. Oncogenes play 
important roles in promoting tumorigenesis and they are 
often upregulated epigenetically after liver damage. They 
can influence cell proliferation, invasion, migration, cell 
cycle dysregulation, and other tumor-related phenomena 
like metastasis formation. Being upregulated, they can 
be promising candidates in early HCC detection as well 
as good targets for silencing therapies. A recent example 
is the identification of APEX2 upregulation associated 
with a worse prognosis in overall liver cancer patients’ 
survival [21]. Aberrant methylation of tumor-suppressor 
genes and demethylation of oncogenes are associated with 
HCC malignancy potential. Methylation regulation could 
thus be explored to target genes such as Sal-like proteins 
4, often associated with chronic hepatitis B infection, but 
also for prognostic purposes, as seen by Wu et al. in 2017 
[22].
Gene expression is regulated not only via methylation, 
but also via non-coding RNAs. A class of small non-coding 
RNAs, called miRNAs, is often dysregulated in cancers and 
could be used as excellent biomarkers thanks to miRNAs’ 
expression stability and resistance to endogenous RNase. 
For example, miR-23a has been studied not only in relation 
to HCC screening tests but also in a prognostic scenario, 
dependent on the HCC stage, tumor size, and the presence 
of multiple focal lesions [23].
The aberrant biogenesis of lncRNAs has been implicated 
in the pathogenesis of HCC. LncRNAs are involved in 
many regulative processes through their binding with 
DNA, RNA, proteins, and small peptides, so once their 
expression profile is altered the impact on the cell 
physiology is evident. RNA-sequencing and microarray 
experiments have shown distinct lncRNA expression 
profiles in HCC tissue compared with non-cancerous ones 
[24]. Alteration in the epigenetic silence/activation or in 
the processing patterns of lncRNA with oncogenic function 
has been reported in HCC patients [25]. In this scenario, 
therapeutic strategies aimed to regulate the transcriptions 
levels of lncRNA may lead to positive results, as seen in 
RNA interference experiments [26]. 
Comprehensively, what emerges in literature is an 
increasing interest in the identification of biomarkers 
for both prognosis and therapy. Identification of early 
diagnostic markers able to prevent the development of 
HCC will lead to the consequent possibility to immediately 
target the tumor, limiting its development. A combinational 
approach could be useful to increase diagnosis accuracy, as 
in the case of the GALAD score, and to identify biomarkers 
that could lead to the development of new therapeutic 
strategies based on mechanisms of upregulation, 
downregulation, or delocalization of the biomarkers 
themselves [27-29]. Despite its promising possibilities, 
however, a therapeutic strategy based on the identification 
of effective biomarkers for HCC will be complex and will 
require a deep investigation of many mechanisms before 
Drug Target Clinical trial phase Ref
First line 
treatments
Sorafenib Multikinase inhibitor FDA approved (2007) [11]
Lenvantinib Multikinase inhibitor FDA approved (2018) [12] 
Second line 
treatments
Regoraferib Multikinase inhibitor FDA approved (2017) [13]
Cabozantinib Multikinase inhibitor FDA approved (2019) [14]
Nivolumab Antibody against PD-1 III* [15]
Pembrolizumab Antibody against PD-1 II [16]
*FDA approved Nivolumab in combination with Ipilimumab to treat advanced HCC in 2020.
 Table 1: Summary of small molecule inhibitors used in HCC clinical protocols.
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treatment planning can start. Unfortunately, as we already 
discussed, another major problem in HCC treatment is the 
limited options available to treat patients in an advanced 
stage. 
In this context, over the years our and other laboratories 
have been focused on the Apurinic/apyrimidinic 
endonuclease 1 (APE1) protein, which was proposed as a 
predictive marker in HCC. In a retrospective IHC study, 
the authors demonstrated that extra nuclear accumulation 
of APE1 correlated with a significant reduction of life 
expectancy in HCC patients [30]. More recently, Pascut et 
al. proposed the presence of APE1 in the serum of HCC 
patients as a new diagnostic biomarker and its role as a 
paracrine pro-inflammatory molecule which may modulate 
the inflammatory status of the cancer microenvironment 
[31]. APE1 is a nuclear/mitochondrial protein and it is a 
key component of the base excision repair (BER) pathway. 
The BER pathway is present both in the nucleus and the 
mitochondrial matrix and it is involved in repairing non-
helix-distorting base lesions [32]. We demonstrated that 
APE1 is translocated to mitochondria upon oxidative 
stress, where it contributes in the stability of mitochondrial 
DNA (mtDNA) [33], and that its translocation relies on the 
mitochondrial import pathway MIA [34]. Recently, our 
laboratory more deeply investigated the trafficking and 
localization of APE1 during HCC staging. Our data revealed 
a mitochondrial localization of APE1 that was dependent 
on the Edmondson-Steiner grading and that inversely 
correlated with the levels of mtDNA damage. Grades 1 and 
2 HCC patients showed a significantly higher expression of 
mitochondrial APE1, which accounted for lower levels of 
mtDNA damage observed in the tumor tissue with respect 
to the distal area. In contrast, the strong cytoplasmic 
positivity in Grade 3 was not associated with APE1’s 
mitochondrial accumulation even when accounting for the 
higher number of mtDNA lesions measured [35]. Based 
on this evidence linking the mitochondrial localization 
of APE1 with lower levels of mtDNA damage during the 
early stages of HCC, a possible therapeutic approach based 
on the inhibition of mitochondrial APE1 trafficking and/
or activity in combination with a DNA damaging agent is 
likely to be effective in slowing down tumor development. 
In this frame, our laboratory is developing a peptide-
based approach to inhibit the pathway responsible for 
mitochondrial translocation of APE1.
In conclusion, although in recent years standardized 
diagnostic protocols and therapeutic procedures associated 
with new pharmacological approaches have enhanced 
the success rate extending the life expectancy of HCC 
patients, HCC remains one of the most prevalent neoplasia 
worldwide. Further studies are needed to discover reliable 
and easily accessible early diagnostic markers as well as 
new and more effective therapies.
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